Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Reply to: Clinical impact of high platelet count and high hematocrit, by Marc Sorigue

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Plasma levels of mannose-binding lectin and future risk of venous thromboembolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Towards patient-specific management of trauma hemorrhage: the effect of resuscitation therapy on parameters of thromboelastometry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Recommendations on thromboprophylaxis in major joint arthroplasty - many guidelines, little consensus?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Fatal pneumococcus meningitis in a child with complement factor ficolin-3 deficiency

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

UNLABELLED: ESSENTIALS: The lectin pathway's MASP-1/2 activates coagulation factors but the trigger of the activation is unknown. MASP-1/2 activation was assessed by quantifying complexes between MASPs and antithrombin/C1-inhibitor. Activated platelets and fibrin were demonstrated to activate MASP-1 and MASP-2 both in vitro and in vivo. These findings may represent a crossroad between the complement and the coagulation systems.

SUMMARY:

BACKGROUND: The activated forms of the complement lectin pathway (LP) proteases MASP-1 and MASP-2 are able to cleave the coagulation factors prothrombin, fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor in vitro. In vivo studies also show that MASP-1 is involved in thrombogenesis.

OBJECTIVES: To clarify the not yet identified mechanisms involved in triggering activation of the LP during thrombotic reactions.

METHODS: Novel sandwich-ELISAs for detection of complexes between MASP-1 or MASP-2 and the serpins C1 inhibitor (C1-INH) or antithrombin (AT), were used to specifically detect and quantify the activated forms of MASP-1 and MASP-2.

RESULTS: Activated platelets were shown by flow cytometry to bind Ficolin-1, -2 and -3 but not MBL, which was associated with activation of MASP-1 and MASP-2. We also demonstrated that fibrin and the plasmin-generated fibrin fragment DD in plasma, bind and activate MASP-1 and MASP-2. As demonstrated by the ELISA and SDS-PAGE/Western blotting, the fibrin-associated activation was reflected in a specific inactivation by AT during clotting without the assistance of heparin. In all other cases the MASPs were, as previously reported, inactivated by C1-INH. In systemic lupus erythematosus patients with thrombotic disease and in polytrauma patients, the levels of activated MASP-1 and MASP-2 in complex with both AT and C1-INH were associated with markers of thrombotic disease and contact/coagulation system activation.

CONCLUSIONS: MASP-1 and MASP-2 are activated during blood clotting. This activation is triggered by activated platelets and by the generation of fibrin during thrombotic reactions in vitro and in vivo, and may represent a novel activation/amplification mechanism in thromboinflammation.

OriginalsprogEngelsk
TidsskriftJournal of thrombosis and haemostasis : JTH
Vol/bind14
Udgave nummer3
Sider (fra-til)531-45
Antal sider15
ISSN1538-7933
DOI
StatusUdgivet - mar. 2016

ID: 49459030